ClinicalTrials.gg

Program

velzatinib

Also written as “Velzatinib” and “IDRX-42”.

In GlaxoSmithKline's pipeline, KIT inhibitor​. Its studies are mostly in Gastrointestinal Stromal Tumors · Gastrointestinal Neoplasms, led by GlaxoSmithKline.

Furthest: phase 3, since Oct 17, 20258 company-led studies, 8 open or runningNext primary completion: Jan 12, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline88 open or runningphase 3since Oct 17, 2025Jul 28, 2022Jan 12, 2027phase 1 · NCT07862114
  • Named in GlaxoSmithKline’s own pipeline as velzatinib GSK6042981, phase 3, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 28, 2022First study: phase 1 study in Gastrointestinal NeoplasmsFirst studyNCT05489237 · 276 enrolled · United States, Belgium, China and more
  2. Oct 17, 2025Phase 3 study in Gastrointestinal NeoplasmsNCT07218926 · 450 planned · United States, Australia, Belgium and more
  3. May 6, 2026Phase 3 study in Gastrointestinal Stromal TumorsNCT07585266 · 800 planned · United States, Argentina, Australia and more
  4. Jul 1, 2026Phase 2 study in Gastrointestinal NeoplasmsNCT07689201 · 24 planned · Japan
  5. Sep 22, 2026Phase 2 study in Gastrointestinal NeoplasmsNCT07843641 · 72 planned
  6. Oct 1, 20263 phase 1 studies in Gastrointestinal NeoplasmsNCT07867171, NCT07862114, NCT07859735

Ahead

  1. Jan 12, 2027Primary completion: phase 1 study in Gastrointestinal NeoplasmsNCT07862114
  2. Mar 10, 2027Primary completion: phase 1 study in Gastrointestinal NeoplasmsNCT05489237
  3. Sep 9, 2027Primary completion: phase 1 study in Gastrointestinal NeoplasmsNCT07867171
  4. Nov 29, 2027Primary completion: phase 2 study in Gastrointestinal NeoplasmsNCT07689201

TargetBeta

“KIT inhibitor​”the company's pipeline, read by Claude · source
“An orally bioavailable small molecule inhibitor of multiple mutated forms of mast/stem cell factor receptor KIT (c-Kit; SCFR), ”NCIt, by rule

Other programs on KIT

ProgramCompanyFurthest phaseStudies
imatinibruleNovartisphase 470
regorafenibruleBayerphase 440
AvapritinibruleSanofiphase 410
anlotinibruleSino Biopharmaceuticalphase 340
masitinibruleAB Sciencephase 338
quizartinibruleDaiichi Sankyophase 322
ripretinibruleOno Pharmaceuticalphase 39
seralutinibrulegb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-incphase 38
elenestinibSanofiphase 33
NB-003ruleningbo-newbay-technology-development-co-ltdphase 32
briquilimabrulejasper-therapeutics-incphase 27
BLU-808Sanofiphase 23

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07867171Gastrointestinal Neoplasms1Not yet recruitingSep 9, 202730
NCT07862114Gastrointestinal Neoplasms1Not yet recruitingJan 12, 202736
NCT07859735Gastrointestinal Neoplasms1Not yet recruitingApr 25, 202840
NCT07843641Gastrointestinal Neoplasms2Not yet recruitingJan 31, 203172
NCT07689201Gastrointestinal Neoplasms · Japan2RecruitingNov 29, 202724
NCT07585266Gastrointestinal Stromal Tumors · United States, Argentina, Australia and more3RecruitingAug 30, 2032800
NCT07218926Gastrointestinal Neoplasms · United States, Australia, Belgium and more3RecruitingMay 30, 2028450
NCT05489237Gastrointestinal Neoplasms · United States, Belgium, China and more1Active, not recruitingMar 10, 2027276

How it is read

Names in the registry

  • “Velzatinib”, 6 entries
  • “IDRX-42”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.